Announcement

Collapse
No announcement yet.

EClinicalMedicine . Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • EClinicalMedicine . Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi


    EClinicalMedicine


    . 2023 Feb;56:101800.
    doi: 10.1016/j.eclinm.2022.101800. Epub 2022 Dec 30.
    Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi


    Upendo L Mseka 1 2 , Jonathan Mandolo 1 , Kenneth Nyoni 2 , Oscar Divala 2 , Dzinkambani Kambalame 2 , Daniel Mapemba 2 , Moses Kamzati 2 , Innocent Chibwe 2 , Marc Y R Henrion 1 3 , Kingsley Manda 4 , Deus Thindwa 1 , Memory Mvula 1 , Bright Odala 2 , Raphael Kamng'ona 1 , Nelson Dzinza 4 , Khuzwayo C Jere 1 5 6 , Nicholas Feasey 1 3 , Antonia Ho 7 , Abena S Amoah 8 9 , Melita Gordon 1 5 , Todd D Swarthout 10 , Amelia Crampin 7 8 9 , Robert S Heyderman 10 , Matthew Kagoli 2 , Evelyn Chitsa-Banda 2 , Collins Mitambo 2 , John Phuka 6 , Benson Chilima 2 , Watipaso Kasambara 2 , Kondwani C Jambo 1 3 6 , Annie Chauma-Mwale 2



    Affiliations

    Abstract

    Background: The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the fourth COVID-19 pandemic wave across the southern African region, including Malawi. The seroprevalence of SARS-CoV-2 antibodies and their association with epidemiological trends of hospitalisations and deaths are needed to aid locally relevant public health policy decisions.
    Methods: We conducted a population-based serosurvey from December 27, 2021 to January 17, 2022, in 7 districts across Malawi to determine the seroprevalence of SARS-CoV-2 antibodies. Serum samples were tested for antibodies against SARS-CoV-2 receptor binding domain using WANTAI SARS-CoV-2 Receptor Binding Domain total antibody commercial enzyme-linked immunosorbent assay (ELISA). We also evaluated COVID-19 epidemiologic trends in Malawi, including cases, hospitalisations and deaths from April 1, 2021 through April 30, 2022, collected using the routine national COVID-19 reporting system. A multivariable logistic regression model was developed to investigate the factors associated with SARS-CoV-2 seropositivity.
    Findings: Serum samples were analysed from 4619 participants (57% female; 60% aged 18-50 years), of whom 878/3794 (23%) of vaccine eligible adults had received a single dose of any COVID-19 vaccine. The overall assay-adjusted seroprevalence was 83.7% (95% confidence interval (CI), 79.3%-93.4%). Seroprevalence was lowest among children <13 years of age (66%) and highest among adults 18-50 years of age (82%). Seroprevalence was higher among vaccinated compared to unvaccinated participants (1 dose, 94% vs. 77%, adjusted odds ratio 4.89 [95% CI, 3.43-7.22]; 2 doses, 97% vs. 77%, aOR 6.62 [95% CI, 4.14-11.3]). Urban residents were more likely to be seropositive than those from rural settings (91% vs. 78%, aOR 2.76 [95% CI, 2.16-3.55]). There was at least a two-fold reduction in the proportion of hospitalisations and deaths among the reported cases in the fourth wave compared to the third wave (hospitalisations, 10.7% (95% CI, 10.2-11.3) vs. 4.86% (95% CI, 4.52-5.23), p < 0.0001; deaths, 3.48% (95% CI, 3.18-3.81) vs. 1.15% (95% CI, 1.00-1.34), p < 0.0001).
    Interpretation: We report reduction in proportion of hospitalisations and deaths from SARS-CoV-2 infections during the Omicron variant dominated wave in Malawi, in the context of high SARS-CoV-2 seroprevalence and low COVID-19 vaccination coverage. These findings suggest that COVID-19 vaccination policy in high seroprevalence settings may need to be amended from mass campaigns to targeted vaccination of reported at-risk populations.
    Funding: Supported by the Bill and Melinda Gates Foundation (INV-039481).

    Keywords: Anti-RBD antibodies; COVID-19; Malawi; Omicron; SARS-CoV-2.

Working...
X